Zura Bio Limited (ZURA)

NCM – Цена в реальном времени. Валюта: USD

5.35

+0.81 (17.84%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

5.40

+0.05 (0.93%)

После закрытия: Jun 26, 2026, 7:17 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Zura Bio Limited (ZURA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Zura Bio Limited (ZURA)

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Zura Bio to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Zura Bio Limited (ZURA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Zura Bio Limited (ZURA)

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Zura Bio to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)